Iceland’s Coripharma Moves From Start-Up To Growth
CEO Jónína Guðmundsdóttir Highlights Niche Focus And ESG Goals
Icelandic out-licensing and contract manufacturing firm Coripharma is moving from the start-up phase to fully-fledged growth, with a particular focus on niche generics and a firm eye on environmental and sustainability aspects, CEO Jónína Guðmundsdóttir tells Generics Bulletin.
You may also be interested in...
The final shortlist of contenders has been unveiled for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt on 2 November.
Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.
Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.